APA (7th ed.) Citation

Francesca Fortunato, Rosa Prato, Giuseppina Iannelli, Leonardo Ascatigno, Daniela Loconsole, Pier Luigi Lopalco, & Domenico Martinelli. (2023). Safety of heterologous ChAdOx1-S/BNT162b2 primary schedule versus homologous BNT162b2 vaccination: Insights from an Italian post-marketing study, 2021. Taylor & Francis Group.

Chicago Style (17th ed.) Citation

Francesca Fortunato, Rosa Prato, Giuseppina Iannelli, Leonardo Ascatigno, Daniela Loconsole, Pier Luigi Lopalco, and Domenico Martinelli. Safety of Heterologous ChAdOx1-S/BNT162b2 Primary Schedule Versus Homologous BNT162b2 Vaccination: Insights from an Italian Post-marketing Study, 2021. Taylor & Francis Group, 2023.

MLA (9th ed.) Citation

Francesca Fortunato, et al. Safety of Heterologous ChAdOx1-S/BNT162b2 Primary Schedule Versus Homologous BNT162b2 Vaccination: Insights from an Italian Post-marketing Study, 2021. Taylor & Francis Group, 2023.